Phibro Animal Stock Price, News & Analysis

Phibro Animal Health Corporation (PAHC) reported strong Q3 FY2025 financial results, with net sales increasing 32% to $347.8 million and net income rising to $20.9 million. The company's performance was driven by the successful integration of the Zoetis MFA business and Phibro Forward initiatives. The Animal Health segment grew 42%, with MFA & Other product sales up 68%. The company updated its FY2025 guidance, projecting net sales of $1.26-1.29 billion and adjusted EBITDA of $177-183 million. Gross profit increased 31% to $104.6 million, while adjusted EBITDA rose 85% to $54.9 million. The company maintains a strong balance sheet with a 3.0x gross leverage ratio and $70.4 million in cash and short-term investments.

Phibro Animal Health Corporation (NASDAQ: PAHC) has announced a quarterly cash dividend declaration. The company's Board of Directors has approved a dividend payment of $0.12 per share for both Class A and Class B common stock. The dividend will be paid on June 25, 2025, to stockholders who are registered as of the close of business on June 4, 2025.

Phibro Animal Health (Nasdaq: PAHC) has scheduled its third quarter financial results announcement for Wednesday, May 7, 2025, after market close. The company will hold a conference call and webcast to discuss the results on Thursday, May 8, 2025, at 9:00 AM Eastern Time.

Investors can access the presentation slides and webcast through https://investors.pahc.com. The conference call will be available via phone at +1 (888) 330-2022 for U.S. and Canada callers, or +1 (365) 977-0051 for international participants, using conference ID 3927884. A replay of the webcast will be made available approximately two hours after the event concludes.

Phibro Animal Health (Nasdaq: PAHC) has announced its participation in the upcoming Barclays Annual Global Healthcare Conference. Chief Financial Officer Glenn David will present to financial analysts and investors on Thursday, March 13, 2025, at 9:00 AM ET at the Loews Miami Beach Hotel.

The presentation will be accessible through a live audio stream on the company's investor relations website at https://investors.pahc.com. For those unable to attend, a replay of the session will be made available and archived on the same platform.

Phibro Animal Health (Nasdaq: PAHC) has announced its participation in the upcoming Bank of America 2025 Virtual Animal Health Summit. The company's Chief Financial Officer, Glenn David, will present to financial analysts and investors on Thursday, February 27, 2025, at 10:50 AM ET.

The presentation will be accessible through a live audio stream on Phibro's Investor Relations website at investors.pahc.com. For those unable to attend the live session, a replay will be made available and archived on the company's website for future reference.

Phibro Animal Health (PAHC) reported strong Q2 FY2025 financial results with significant growth across key metrics. Net sales reached $309.3 million, up 24% year-over-year, while net income increased to $3.2 million. The company's adjusted EBITDA grew 64% to $48.2 million, and adjusted diluted EPS rose 64% to $0.54.

The growth was primarily driven by the Animal Health segment and successful integration of the Zoetis Medicated Feed Additive portfolio acquired on October 31, 2024. The company updated its FY2025 guidance, projecting net sales between $1.25-1.30 billion and adjusted EBITDA of $172-180 million.

The company maintains a solid balance sheet with $67.1 million in cash and short-term investments, and a gross leverage ratio of 3.1x as of December 31, 2024.

Phibro Animal Health (Nasdaq: PAHC) has announced its Board of Directors has declared a quarterly cash dividend. The dividend of $0.12 per share will be paid on both Class A and Class B common stock. Shareholders who are registered as stockholders of record at the close of business on March 5, 2025, will receive the dividend payment on March 26, 2025.

Phibro Animal Health (PAHC) has appointed Joyce J. Lee as a Class II director, expanding its Board to nine members. Lee, who will serve as an independent director, brings extensive experience from her recent role as President of Cobb Vantress and previous executive positions at Elanco, Bayer Animal Health, and Zoetis.

Lee's expertise spans global genetics production, general management, strategy, sales, marketing, R&D, engineering, manufacturing, and IT. A recipient of the 2018 Feather in Her Cap Award, she holds a BBA from Baylor University and an MBA in Healthcare Administration from Jacksonville University. Her appointment strengthens the board's independent representation to six directors.

Lee's background includes significant experience in corporate governance, having served on both corporate governance and nomination committees for over two years and an audit committee for more than five years at a publicly traded company.

Phibro Animal Health (PAHC) has scheduled its second quarter financial results announcement for Wednesday, February 5, 2025, after market close. The company will follow up with a conference call and webcast on Thursday, February 6, 2025, at 9:00 AM Eastern Time.

Investors can access the presentation through the company's investor relations website at https://investors.pahc.com. Additionally, participants can join via phone by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international calls, using conference ID 3927884. A replay of the webcast will be made available approximately two hours after the event concludes.